mFOLFOX6

Org: Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik Dr. Hancken GmbH,

Clinical trial

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM): An Open Label, Prospective, Single Arm Clinical Trial

Status: Active (not recruiting), Estimated PCD: 2023-03-31

Clinical trial

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2026-01-01

Abstract

Adjuvant chemotherapy in clinical local advanced CRC following preoperational therapies and pT0-3N0M0 diagnosis (CANWATCH).

Org: Kunming, China,

Abstract

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).

Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,

Clinical trial

PD-1 Antibody(Tislelizumab) Plus Irinotecan Combined With POF in Treatment Naive Advanced Gastric Cancer: A Phase II Study.

Status: Not yet recruiting, Estimated PCD: 2024-04-11

Clinical trial

A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Status: Recruiting, Estimated PCD: 2027-10-31

Abstract

Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort.

Org: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China, Huangshi Central Hospital of Hubei Province, Huangshi, China, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, Hubei Cancer Hosp, Wuhan, China, Department of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China,

Clinical trial

EFFIPEC - Efficacy of Hyperthermic Intraperitoneal Chemotherapy, Single-arm Phase I Study, Followed by an Open-label, Randomized, Controlled Registry-based Phase III Trial

Status: Recruiting, Estimated PCD: 2025-12-01

Abstract

BreAK CRC, a first-in-human phase I/II trial of STC-1010, a new allogenic cancer vaccine for advanced or metastatic unresectable colorectal cancer.

Org: Centre Hospitalier Universitaire de Poitiers, Poitiers, France, Department of Clinical Research, Centre Léon Bérard, Lyon, France, 4 rue Eric de Cromières, Clermont-Ferrand, France, Brenus Pharma, Clermont-Ferrand, France, Medical Oncology Department, Centre Georges-François Leclerc, University of Bourgogne Franche-Comté, Dijon, France,

Abstract

Adjuvant chemotherapy with mFOLFOXIRI versus mFOLFOX6 in MRD-positive stage II-III colorectal cancer.

Org: Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, SYSU, Guangzhou, China, The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, China, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Third Affiliated Hospital of Kunming Medical University, Kunming, China, Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,

Clinical trial

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2026-09-01

Abstract

Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis.

Org: the Naval Medical University,

Clinical trial

S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Status: Completed, Estimated PCD: 2019-04-01

Clinical trial

A Phase II, Prospective, Multicenter Study of Cadonilimab in Combination With FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer.

Status: Recruiting, Estimated PCD: 2024-03-01

Clinical trial

Prospective Safety Study of Sintilimab Combined With XELOX Plus Bevacizumab for Preoperative Neoadjuvant Therapy of CRLM Patients With pMMR/MSS Status

Status: Active (not recruiting), Estimated PCD: 2023-10-30

Clinical trial

Efficacy and Safety of Neoadjuvant Cadonilimab and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer : a Prospective, Open-label, Single-Arm Phase II Study

Status: Not yet recruiting, Estimated PCD: 2025-03-01

Clinical trial

NALIRIFOX as Perioperative Treatment in Patients With High-risk Resectable Pancreatic Cancer : a Multicenter, Randomized, Open-label Trial

Status: Not yet recruiting, Estimated PCD: 2025-04-01

Clinical trial

A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Status: , Estimated PCD: 2025-05-01

Clinical trial

Rectal Artery Infusion Chemotherapy of Oxaliplatin Plus Capecitabine Combined With Anti-PD1 Antibody After Induction Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer：a Prospective Single-arm Phase II Study

Status: Recruiting, Estimated PCD: 2024-04-25

Clinical trial

A Randomized Phase II Study of Systemic Chemotherapy With or Without HAI FUDR/Dexamethasone in Patients With Unresectable Intrahepatic Cholangiocarcinoma

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

A Single-arm Multicentre Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Who Have Not Previously Received Therapy for Metastatic Adenocarcinoma of the Pancreas

Status: Not yet recruiting, Estimated PCD: 2025-08-28

Clinical trial

Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer. A Randomized Phase II Marker Trial

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-Selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Paediatric Hepatic International Tumour Trial

Status: Active (not recruiting), Estimated PCD: 2026-08-01

Clinical trial

A Single-center, Single-arm, Open-label Clinical Study of Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Status: Active (not recruiting), Estimated PCD: 2024-01-01

Clinical trial

Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Status: Recruiting, Estimated PCD: 2027-12-31

Clinical trial

A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2023-05-06

Clinical trial

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2025-02-01

Clinical trial

TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial

Status: Not yet recruiting, Estimated PCD: 2026-06-22

Clinical trial

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

Randomised Study to Investigate FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab as First-line Treatment of BRAF-mutated Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2023-11-01

Clinical trial

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 Alone in Locally Advanced Colorectal Cancer: a Randomized Control Phase II Study (OPTICAL-2)

Status: Recruiting, Estimated PCD: 2024-12-15

Clinical trial

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

A Phase Ib, Dose Escalation Study of Lithium When Added to Standard Chemotherapy of Oxaliplatin and Capecitabine in Patients With Advanced Oesophago-Gastric or Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

A Phase II Study of Total Neoadjuvant Therapy in Rectal Cancer

Status: Recruiting, Estimated PCD: 2026-11-16

Clinical trial

A Single-arm, Multicenter, Phase II Clinical Study of Chemoradiotherapy Followed by Tislelizumab Combined With Chemotherapy for Organ Preservation in Resectable Low Rectal Cancer：the RELIEVE-01 Study

Status: Not yet recruiting, Estimated PCD: 2025-12-01

Clinical trial

TAS-102 in Combination With Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-03-31

Clinical trial

Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer

Status: Active (not recruiting), Estimated PCD: 2023-06-01

Clinical trial

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI)

Status: Active (not recruiting), Estimated PCD: 2026-02-01

Clinical trial

A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas

Status: Completed, Estimated PCD: 2020-09-11

Clinical trial

NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2025-04-15

Clinical trial

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)

Status: Active (not recruiting), Estimated PCD: 2025-04-30

Clinical trial

Neoadjuvant Combination of Serplulimab and Bevacizumab With FOLFOX Versus FOLFOX Alone for Resectable Liver Metastases in RAS/BRAF Wild-Type, pMMR/MSS Colorectal Cancer Patients

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Biomarker-oriented Study of Pembrolizumab in Combination With Chemotherapy in Chemotherapy -naïve Advanced Pancreatic Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2025-04-02

Clinical trial

An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)

Status: Completed, Estimated PCD: 2023-11-08

Clinical trial

A Multicentre Randomised Phase II Trial of Neo-adjuvant Chemotherapy Followed by Surgery vs. Neo-adjuvant Chemotherapy and Subsequent Chemoradiotherapy Followed by Surgery vs. Neo-adjuvant Chemoradiotherapy Followed by Surgery in Resectable Gastric Cancer

Status: Active (not recruiting), Estimated PCD: 2025-04-01

Clinical trial

Systemic Chemotherapy With or Without Hepatic Arterial Infusion With Floxuridine in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective, Randomised, Controlled Study

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Pilot Trial of Pembrolizumab Plus Chemoradiotherapy in Participants With Unresectable Gastroesophageal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-07-18

Clinical trial

A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory Neuroblastoma

Status: Terminated, Estimated PCD: 2019-07-01

Clinical trial

Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Status: Completed, Estimated PCD: 2022-06-16

Clinical trial

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status: Recruiting, Estimated PCD: 2025-04-15

Clinical trial

A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

Status: Recruiting, Estimated PCD: 2029-12-31

Clinical trial

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX in Patients With Initially Unresectable Colorectal Liver Metastasis

Status: Active (not recruiting), Estimated PCD: 2022-12-30

Clinical trial

A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

XELOX for 4 Months Versus 6 Months as Adjuvant Chemotherapy in Gastric Cancer After D2 Resection (LOMAC)

Status: Active (not recruiting), Estimated PCD: 2026-08-01

Clinical trial

A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Status: Completed, Estimated PCD: 2021-09-21

Clinical trial

A Multicenter, Single-Arm Open Label Phase II Trial of Cryoablation in Combination With Pembrolizumab or Avelumab in Patients With Metastatic Urothelial Carcinoma

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade

Status: Completed, Estimated PCD: 2020-03-14

Clinical trial

A Phase II Study of Perioperative Pembrolizumab-Based Therapy in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Prior to Cytoreductive Nephrectomy or Metastasectomy

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

Stimulating Immune Response With Neoadjuvant Human Papilloma Virus (HPV)-16 Specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)

Status: Not yet recruiting, Estimated PCD: 2028-07-01

Clinical trial

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

Perioperative S-1 Plus Oxaliplatin Combined With Serplulimab or Placebo for Locally Advanced Gastric Adenocarcinoma With Proficient Mismatch Repair: a Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study

Status: Recruiting, Estimated PCD: 2026-04-30

Clinical trial

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction : a Prospective，Single-arm, Phase II Trial (TASTE Trial)

Status: Not yet recruiting, Estimated PCD: 2025-08-31

Clinical trial

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2024-11-28

Clinical trial

FOLFOX Via Hepatic Artery Infusion Chemotherapy (HAI) Plus Systemic Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A Prospective, Randomized, Controlled Clinical Study

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

Status: Completed, Estimated PCD: 2022-02-01

Clinical trial

A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Status: Terminated, Estimated PCD: 2015-12-23

Clinical trial

Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Status: Completed, Estimated PCD: 2023-06-07

Clinical trial

The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer: A Randomized Controlled Trial

Status: Completed, Estimated PCD: 2022-10-31

Clinical trial

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With Simultaneous Integrated Boost Intensity-modulated Radiotherapy in the Treatment of Locally Advanced Rectal Cancer

Status: Recruiting, Estimated PCD: 2024-08-31

Clinical trial

A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Status: Active (not recruiting), Estimated PCD: 2023-06-22

Clinical trial

A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene

Status: Not yet recruiting, Estimated PCD: 2027-07-13

Clinical trial

A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas

Status: Active (not recruiting), Estimated PCD: 2023-05-03

Clinical trial

A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive Enhancing IDH-1 Mutant Glioma

Status: Recruiting, Estimated PCD: 2025-03-31

Clinical trial

Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination With Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2025-04-01

Clinical trial

A Phase 2 Study of Intravenous Pembrolizumab and Intratumorally Injected Autologous Dendritic Cells (DCs) in Refractory Colorectal Cancer (CRC)

Status: Not yet recruiting, Estimated PCD: 2026-10-01

Clinical trial

Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2022-04-01

Clinical trial

Exploratory Study of Gastric Cancer Organoids in the Screening of Neoadjuvant Chemotherapy and Immunotherapy Drugs

Status: Recruiting, Estimated PCD: 2024-06-28

Clinical trial

A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics

Status: Recruiting, Estimated PCD: 2029-06-01

Clinical trial

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)

Status: Active (not recruiting), Estimated PCD: 2026-07-01

Clinical trial

Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or Pralatrexate

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma

Status: Terminated, Estimated PCD: 2023-11-01

Clinical trial

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Status: Recruiting, Estimated PCD: 2027-01-31

Clinical trial

A Phase II Clinical Study to Evaluate the Efficacy and Safety of QLS31905 and/or QL1706 Combination Chemotherapy for the Treatment of CLDN18.2-Positive Advanced Malignant Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2026-06-30

Clinical trial

A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2028-12-31

Clinical trial

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2022-09-09

Clinical trial

A Randomized, Open-Label, Multicenter Phase III Clinical Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for PD-L1 Positive Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Status: Active (not recruiting), Estimated PCD: 2025-09-01

Clinical trial

Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients.

Status: Completed, Estimated PCD: 2021-06-15

Clinical trial

Nivolumab and CAPOX in Patients With FGFR2/PD-L1-positive Metastatic Gastric Adenocarcinoma: a Single-arm, Phase 2 Study

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Status: Recruiting, Estimated PCD: 2030-07-01

Clinical trial

A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies

Status: Completed, Estimated PCD: 2022-10-20

Clinical trial

A Phase 1 Trial of Naptumomab Estafenatox (NAP) in Combination With Pembrolizumab (Pembro) Preceded by Obinutuzumab (Obi) in Patients With Urothelial Cancers

Status: Withdrawn, Estimated PCD: 2025-12-01

Clinical trial

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study

Status: Recruiting, Estimated PCD: 2024-09-30

Clinical trial

A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-29

Clinical trial

A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma

Status: Terminated, Estimated PCD: 2022-07-26

Clinical trial

Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

Phase ll Trial of Docetaxel/Pembrolizumab Combination Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2024-01-31

Clinical trial

A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas

Status: Recruiting, Estimated PCD: 2024-12-23

Clinical trial

A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)

Status: Terminated, Estimated PCD: 2023-08-16

Clinical trial

The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients.

Status: Recruiting, Estimated PCD: 2029-12-31

Clinical trial

Neoadjuvant Tislelizumab With Oxaliplatin and Capecitabine in Microsatellite Stable, Locally Advanced Colon Cancer: A Prospective, Single-arm, Single-center, Exploratory Phase II Clinical Study

Status: Recruiting, Estimated PCD: 2026-11-30

Clinical trial

Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-100M in Melanoma Brain Metastases

Status: Recruiting, Estimated PCD: 2025-03-06

Clinical trial

A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma

Status: Recruiting, Estimated PCD: 2025-04-01

Clinical trial

Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-10-01

Clinical trial

A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer

Status: , Estimated PCD: 2025-12-31

Clinical trial

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma

Status: Active (not recruiting), Estimated PCD: 2022-01-02

Clinical trial

DISCERN: Dual Immune Strategy Versus Single Checkpoint Inhibition Efficacy Response in PDL-1 Negative Non-Small Cell Lung Cancer (NSCLC)

Status: Not yet recruiting, Estimated PCD: 2027-01-30

Clinical trial

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status: Active (not recruiting), Estimated PCD: 2024-02-15

Clinical trial

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Status: Not yet recruiting, Estimated PCD: 2026-06-02

Clinical trial

A Phase II Study of Epacadostat and Pembrolizumab in Patients With Imatinib Refractory Advanced Gastrointestinal Stromal Tumors

Status: Terminated, Estimated PCD: 2020-08-19

Clinical trial

Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab

Status: Completed, Estimated PCD: 2022-07-22

Clinical trial

A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With KRAS Mutant Peptide in Combination With Anti-PD-1 Antibody/Anti-CTLA4 Antibody for Local Advanced/Metastatic Solid Tumors.

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

A Phase-II Open-label Study of Pembrolizumab and Lenvatinib in Patients With Advanced Stage Hepatocellular Carcinoma Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Status: Active (not recruiting), Estimated PCD: 2024-10-01

Clinical trial

A Phase II Clinical Trial Evaluating The Combination Of Lenvatinib Plus Pembrolizumab In Patients With Treatment Naive Metastatic Uveal Melanoma

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

Status: Recruiting, Estimated PCD: 2027-07-31

Clinical trial

A Phase Ib Study of Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Status: Completed, Estimated PCD: 2020-03-17

Clinical trial

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

Status: Not yet recruiting, Estimated PCD: 2026-02-28

Clinical trial

A Prospective Phase II Trial of Immunotherapy Combined With Short-course Radiotherapy in Early Low Rectal Cancer

Status: Recruiting, Estimated PCD: 2024-11-01

Clinical trial

A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma

Status: Active (not recruiting), Estimated PCD: 2026-03-20

Clinical trial

Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2024-07-31

Clinical trial

A Phase II, Open-Label, Single-Arm Trial Using KEYTRUDA (Pembrolizumab) as Initial Systemic Therapy in the Treatment of Advanced Mycosis Fungoides

Status: Active (not recruiting), Estimated PCD: 2024-10-11

Clinical trial

1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

A Phase 2 Study of Preoperative Pembrolizumab and Chemotherapy Followed by Adjuvant Pembrolizumab in Resectable Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-05-20

Clinical trial

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

Status: Recruiting, Estimated PCD: 2028-12-01

Clinical trial

Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet Chemotherapy

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

A Multicenter, Randomized Controlled Trial of Preoperative Sequential Short-course Radiation Therapy and Oxaliplatin-based Consolidation Chemotherapy for Locally Advanced Rectal Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)

Status: Completed, Estimated PCD: 2021-04-08

Clinical trial

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-06-15

Clinical trial

Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Status: Recruiting, Estimated PCD: 2026-09-01

Clinical trial

Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-11-27

Clinical trial

A Pilot Study of Hypoxia as a Potential Resistance Mechanism to PD-1 Checkpoint Blockade Therapy in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (HYPERION)

Status: Recruiting, Estimated PCD: 2023-09-01

Clinical trial

Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker

Status: Terminated, Estimated PCD: 2019-03-22

Clinical trial

Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Single Center, Open Label Trial, Phase 2/3

Status: Recruiting, Estimated PCD: 2027-12-01

Clinical trial

Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation

Status: Withdrawn, Estimated PCD: 2022-10-31

Clinical trial

Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Status: Terminated, Estimated PCD: 2018-10-18

Clinical trial

Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours

Status: Completed, Estimated PCD: 2020-05-22

Clinical trial

Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer

Status: Completed, Estimated PCD: 2022-05-19

Clinical trial

Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL)

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer: A Multicenter, Phase II Study

Status: Completed, Estimated PCD: 2022-02-28

Clinical trial

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

Status: Completed, Estimated PCD: 2022-12-26

Clinical trial

A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology

Status: Active (not recruiting), Estimated PCD: 2024-03-31

Clinical trial

Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Immunotherapy Refractory Esophagogastric Adenocarcinoma

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-02-01

Clinical trial

Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-07-17

Clinical trial

A Phase II Study of Pembrolizumab, Olaparib, and Temozolomide in Patients With Glioma

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

Pembrolizumab for Newly Diagnosed Glioblastoma: a Prospective, Open-label, Single-arm, Multicenter Phase II Study

Status: Active (not recruiting), Estimated PCD: 2026-04-30

Clinical trial

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Status: Recruiting, Estimated PCD: 2025-02-28

Clinical trial

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Status: Recruiting, Estimated PCD: 2026-03-31

Clinical trial

Phase II Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2025-02-28

Clinical trial

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Open-label, Dose-escalation Trial to Evaluate the Safety and Pharmacokinetics of GEN1046 in Japanese Subjects With Advanced Solid Malignancies

Status: Active (not recruiting), Estimated PCD: 2024-11-12

Clinical trial

A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation Versus Chemoradiotherapy For Early Rectal Cancer

Status: Not yet recruiting, Estimated PCD: 2030-01-30

Clinical trial

A Randomized Phase II Study Of Eribulin Mesylate With Or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Status: Completed, Estimated PCD: 2018-10-11

Clinical trial

Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)

Status: Active (not recruiting), Estimated PCD: 2024-11-02

Clinical trial

A Pilot Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Status: Recruiting, Estimated PCD: 2024-11-30

Clinical trial

A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma

Status: Terminated, Estimated PCD: 2023-07-25

Clinical trial

Phase II Study of Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer (Neo-ICEBOAT Study)

Status: Recruiting, Estimated PCD: 2024-11-01

Clinical trial

A Multicenter, Open, Prospective Study of Prognostic Value and Benefit From Adjuvant Immunotherapy of Stage III Papillary Renal Cell Carcinoma Based on Multi-classifier System

Status: Not yet recruiting, Estimated PCD: 2030-12-01

Clinical trial

A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma

Status: Terminated, Estimated PCD: 2021-11-01

Clinical trial

Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Single-arm, Open-label, Single-center Phase II Clinical Study of Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Status: Not yet recruiting, Estimated PCD: 2024-08-01

Clinical trial

Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Status: Recruiting, Estimated PCD: 2028-05-01

Clinical trial

Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy

Status: Active (not recruiting), Estimated PCD: 2021-10-01

Clinical trial

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus

Status: Active (not recruiting), Estimated PCD: 2024-05-01

Clinical trial

Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study

Status: , Estimated PCD: 2024-12-31

Clinical trial

A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Status: Active (not recruiting), Estimated PCD: 2024-08-31

Clinical trial

Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination With Intratumoral SD-101 Therapy in Patients With Hormone-Naïve Oligometastatic Prostate Cancer Receiving Stereotactic Body Radiation Therapy and Intermittent Androgen Deprivation Therapy

Status: Active (not recruiting), Estimated PCD: 2024-10-31

Clinical trial

Phase 2 Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies

Status: Completed, Estimated PCD: 2018-05-29

Clinical trial

A Phase II Study of Open Label Low Dose Ipilimumab in Combination With Pembrolizumab in Metastatic Melanoma Patients With Brain Metastases

Status: Active (not recruiting), Estimated PCD: 2024-08-31

Clinical trial

The Effect of Intraperitoneal Immune Checkpoint Inhibitor on Malignant Ascites of Patients With Gastric, Pancreatic or Biliary Tract Cancer

Status: , Estimated PCD: 2026-12-01

Clinical trial

Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma

Status: Active (not recruiting), Estimated PCD: 2017-12-30

Clinical trial

Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma

Status: Terminated, Estimated PCD: 2015-07-01

Clinical trial

A Pilot Study to Evaluate the Efficacy and Safety of Preoperative Olaparib Monotherapy and Preoperative Olaparib Plus Pembrolizumab Combination Therapy in Patients With HRD-Positive Stage III or IV Advanced Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer

Status: Completed, Estimated PCD: 2023-06-30

Clinical trial

A Pilot Trial of Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Status: Recruiting, Estimated PCD: 2028-07-01

Clinical trial

Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer: a Phase Ib/II, Multicenter, Open-label Trial

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Status: Recruiting, Estimated PCD: 2026-11-04

Clinical trial

Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Status: Recruiting, Estimated PCD: 2026-06-01

Clinical trial

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Status: , Estimated PCD: 2028-06-30

Clinical trial

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Status: Recruiting, Estimated PCD: 2028-06-15

Clinical trial

A Phase Ib Trial of Vaginal Cuff Brachytherapy + Pembrolizumab (MK3475) Followed by 3 Cycles of Dose Dense Paclitaxel/q 21 Day Carboplatin + Pembrolizumab (MK3475) in High Intermediate Risk Endometrial Cancer

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

Phase II Study Evaluating Holmium-166 TARE Followed by Maintenance Therapy in Liver Limited Unresectable Colorectal Cancer Patients After First-line Chemotherapy and Target Agents

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

A Prospective，Multicenter，Randomized Trial of Biweekly Single-dose Actinomycin-D Versus Multi-day Methotrexate Protocol for the Treatment of Low-risk Gestational Trophoblastic Neoplasia

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

Pilot Study of INCB081776 Together With Palliative Radiation and Anti-PD-1 Checkpoint Blockade With Pembrolizumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Status: Recruiting, Estimated PCD: 2026-08-01

Clinical trial

Intralesional Influenza Vaccine for Patients With Melanoma

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal/Gastroesophageal Junction Adenocarcinoma (PHOX)

Status: Recruiting, Estimated PCD: 2026-05-30

Clinical trial

A Window of Opportunity (WoO) Study Evaluating Pembrolizumab With or Without Olaparib in Tertiary Lymphoid Structures (TLS)-Positive Selected Resectable Soft Tissue Sarcoma (STS) Followed by Adjuvant Pembrolizumab

Status: Not yet recruiting, Estimated PCD: 2026-09-01

Clinical trial

Safety and Immunological Effects of Ablative Radiotherapy Followed by Pembrolizumab in Patients With Advanced Adrenocortical Carcinoma

Status: Recruiting, Estimated PCD: 2026-09-27

Clinical trial

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Status: Active (not recruiting), Estimated PCD: 2026-10-28

Clinical trial

LCI-BRE-H2N-PEPP-001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients With Metastatic HER2-Negative Breast Cancer (The PePPy Trial)

Status: Completed, Estimated PCD: 2021-07-29

Clinical trial

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Status: Recruiting, Estimated PCD: 2026-08-19

Clinical trial

Pilot Study of Dual Checkpoint Inhibition Followed by Immuno-Chemoradiation in Patients With Resectable Gastric Adenocarcinoma (Concept ID 2016-NIV-0551)

Status: Active (not recruiting), Estimated PCD: 2026-12-30

Clinical trial

A Window of Opportunity Phase II Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy

Status: Completed, Estimated PCD: 2023-05-01

Clinical trial

A Pilot Study of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma

Status: Completed, Estimated PCD: 2023-01-27

Clinical trial

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, and Sabestomig

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma

Status: Completed, Estimated PCD: 2021-10-18

Clinical trial

A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary

Status: Active (not recruiting), Estimated PCD: 2021-02-01

Clinical trial

An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

HR070803 in Combination With Oxaliplatin Plus Tegafur Versus HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate as Adjuvant Therapy for Pancreatic Cancer: A Multicenter, Multi-cohort, Randomized, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2027-03-01

Clinical trial

A Phase IIb Pilot Study to Assess the Efficacy, Safety, and Pharmacodynamics Effects of Pembrolizumab and BL-8040 in Patients With Metastatic Pancreatic Cancer

Status: Completed, Estimated PCD: 2023-10-06

Clinical trial

A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma

Status: Completed, Estimated PCD: 2022-08-08

Clinical trial

Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia

Status: Active (not recruiting), Estimated PCD: 2022-03-18

Clinical trial

A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2022-06-07

Clinical trial

Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)

Status: Active (not recruiting), Estimated PCD: 2024-03-09

Clinical trial

IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC

Status: Terminated, Estimated PCD: 2024-04-22

Clinical trial

Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2027-07-01

Clinical trial

A Phase 1/2 Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Status: Recruiting, Estimated PCD: 2026-08-01

Clinical trial

Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2028-11-08

Clinical trial

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

Status: Active (not recruiting), Estimated PCD: 2020-09-30

Clinical trial

A Phase II Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

Status: Completed, Estimated PCD: 2023-03-10

Clinical trial

A Phase 2 Clinical Study to Assess Efficacy of Induction Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer: PRIAM

Status: Not yet recruiting, Estimated PCD: 2026-10-14

Clinical trial

A Phase II Study of Reirradiation With NBTXR3 in Patients With Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma

Status: Withdrawn, Estimated PCD: 2022-11-21

Clinical trial

Phase II Study of Pembrolizumab for PD-L1 Gene-Altered, Relapsed/Refractory DLBCL

Status: Recruiting, Estimated PCD: 2025-04-14

Clinical trial

A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Failed Immune Checkpoint Inhibitor

Status: Terminated, Estimated PCD: 2020-08-15

Clinical trial

Phase II Study Evaluating HPV-16 Vaccination (ISA101b) and Pembrolizumab Plus Cisplatin Chemoradiotherapy for "Intermediate Risk" HPV-16 Associated Head and Neck Squamous Cell Carcinoma (HNSCC)

Status: Recruiting, Estimated PCD: 2027-06-30

Clinical trial

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Status: Active (not recruiting), Estimated PCD: 2023-01-10

Clinical trial

A Randomized, Open Labeled Phase II Pilot Study of Total Neoadjuvant Chemotherapy With FLOT ( FLOT-TNT) VS Standard Perioperative FLOT ( FLOTPOP) in Patients With Gastric or GEJ Cancer, and Assessment of CTDNA as Correlative Biological Response

Status: Recruiting, Estimated PCD: 2028-10-01

Clinical trial

Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1

Status: Terminated, Estimated PCD: 2021-06-17

Clinical trial

Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Status: Terminated, Estimated PCD: 2023-01-30

Clinical trial

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above (cHL 001)

Status: Recruiting, Estimated PCD: 2027-10-03

Clinical trial

Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin With Adjuvant Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma

Status: Not yet recruiting, Estimated PCD: 2027-01-01

Clinical trial

A Phase Ib/II Study of Selinexor Plus Pembrolizumab in Cisplatin-Ineligible or Cisplatin-Refractory Patients With Advanced Urothelial Carcinoma

Status: Recruiting, Estimated PCD: 2024-05-01

Clinical trial

Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer

Status: Active (not recruiting), Estimated PCD: 2019-03-26

Clinical trial

Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Status: Withdrawn, Estimated PCD: 2027-01-31

Clinical trial

Pilot Study of an IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Status: Recruiting, Estimated PCD: 2026-06-01

Clinical trial

Pembrolizumab and Trastuzumab in Combination With FLOT in the Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma - A Phase II Trial of the AIO Study Group - PHERFLOT -

Status: Active (not recruiting), Estimated PCD: 2027-10-01

Clinical trial

A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)

Status: Completed, Estimated PCD: 2018-02-06

Clinical trial

Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting

Status: Active (not recruiting), Estimated PCD: 2023-10-31

Clinical trial

Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II Trial

Status: Recruiting, Estimated PCD: 2026-03-30

Clinical trial

A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status

Status: Completed, Estimated PCD: 2017-02-28

Clinical trial

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [NEOMUN]

Status: Completed, Estimated PCD: 2021-10-30

Clinical trial

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)

Status: Recruiting, Estimated PCD: 2029-10-26

Clinical trial

Randomized Phase II Study of NaliCap (Irinotecan Liposome/Capecitabine) Compared to NAPOLI (Irinotecan Liposome/5-fluorouracil/Leucovorin) in Gemcitabine-pretreated Advanced Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in Triple-negative Metastatic Breast Cancer Patients

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

ESSAI DE PHASE III RANDOMISE EVALUANT LE FOLFOX AVEC OU SANS DOCETAXEL (TFOX) EN 1ère LIGNE DE CHIMIOTHERAPIE DES ADENOCARCINOMES OESO-GASTRIQUES LOCALEMENT AVANCES OU METASTATIQUES

Status: Active (not recruiting), Estimated PCD: 2023-04-01

Clinical trial

Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MCPyV-Specific TCRs Combined With Avelumab and Class I MHC-Upregulation in Patients With Metastatic MCC Refractory to PD-1 Axis Blockade

Status: Active (not recruiting), Estimated PCD: 2024-01-10

Clinical trial

A Pilot and Feasibility Study of PD-1 Blockade With Nivolumab in Combination With Chemotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2025-04-15

Clinical trial

Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET

Status: , Estimated PCD: 2025-04-01

Clinical trial

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.

Status: Terminated, Estimated PCD: 2021-03-10

Clinical trial

A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer

Status: Completed, Estimated PCD: 2021-12-01

Clinical trial

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Status: Completed, Estimated PCD: 2020-04-21

Clinical trial

A Phase 1 Study of Irreversible Electroporation and Pembrolizumab Immunotherapy in Locally Advanced Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2027-04-01

Clinical trial

A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

Status: Active (not recruiting), Estimated PCD: 2015-02-25

Clinical trial

KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

Status: Recruiting, Estimated PCD: 2027-07-01

Clinical trial

A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status: Active (not recruiting), Estimated PCD: 2020-04-09

Clinical trial

Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation

Status: Completed, Estimated PCD: 2022-08-03

Clinical trial

A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Patient-unique Tumor-specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers

Status: , Estimated PCD: 2026-04-15

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-04-21

Clinical trial

Identification of Predictive Biomarkers of Response to Chemotherapy and Immune Checkpoint Inhibitors in Early Triple Negative Breast Cancer: an Integrative Multiomics Platform

Status: Recruiting, Estimated PCD: 2026-12-01

Clinical trial

NEOPRISM-CRC : Neoadjuvant Pembrolizumab Stratified to Tumour Mutation Burden for High Risk Stage 2 or Stage 3 MMR-deficient Colorectal Cancer

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-04-14

Clinical trial

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Status: , Estimated PCD: 2025-12-31

Clinical trial

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Phase II Study of AVELUMAB and CETUXIMAB and Modified FOLFOXIRI as Initial Therapy for RAS Wild-type Unresectable Metastatic Colorectal Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2023-06-28

Clinical trial

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Patients by Transient Addition of BRAF and MEK Inhibitors Followed by Pembrolizumab: A Pivotal Open Label, Single-site Study

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.

Status: Completed, Estimated PCD: 2021-01-12

Clinical trial

Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

Status: Completed, Estimated PCD: 2021-05-03

Clinical trial

A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients With Performance Status 2 With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Recruiting, Estimated PCD: 2025-07-31

Clinical trial

Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC)

Status: Withdrawn, Estimated PCD: 2023-07-26

Clinical trial

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2027-11-01

Clinical trial

Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study

Status: Active (not recruiting), Estimated PCD: 2024-06-12

Clinical trial

Phase I/Ib Study of Combined Pembrolizumab Plus Guadecitabine and Mocetinostat for Patients With Advanced NSCLC (DOSE SELECTION)

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

A Phase II Study of Pembrolizumab in Combination With Circulating Tumor DNA Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY Trial (Squamous Cell Carcinoma of Head and Neck Response-Guided Therapy)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Status: Recruiting, Estimated PCD: 2025-04-30

Clinical trial

Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Status: Active (not recruiting), Estimated PCD: 2025-12-01

Clinical trial

Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status: Completed, Estimated PCD: 2022-12-22

Clinical trial

A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant Mesothelioma

Status: Terminated, Estimated PCD: 2021-12-31

Clinical trial

Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Status: Completed, Estimated PCD: 2022-05-01

Clinical trial

Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer - the FLU-IMMUNE Trial.

Status: Not yet recruiting, Estimated PCD: 2025-09-01

Clinical trial

A Phase II Open Label, Single Arm Study to Evaluate the Efficacy of Pembrolizumab for Leukoplakia

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

A Study of LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer to Evaluate the Safety, Tolerability and Preliminary Efficacy

Status: Recruiting, Estimated PCD: 2025-07-30

Clinical trial

Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2019-05-17

Clinical trial

Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

Status: , Estimated PCD: 2016-03-01

Clinical trial

The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-03-31

Clinical trial

SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial

Status: Completed, Estimated PCD: 2023-12-14

Clinical trial

A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure

Status: Active (not recruiting), Estimated PCD: 2022-10-01

Clinical trial

A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179

Status: Completed, Estimated PCD: 2020-08-10

Clinical trial

Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembrolizumab + Chemotherapy in Triple Negative Breast Cancer (TNBC)

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase II Study of Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Status: Active (not recruiting), Estimated PCD: 2025-05-01

Clinical trial

Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Status: Withdrawn, Estimated PCD: 2027-07-01

Clinical trial

Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial

Status: , Estimated PCD: 2028-05-01

Clinical trial

A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer

Status: , Estimated PCD: 2005-10-01

Clinical trial

A Multicenter, Open Label, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase II, Multicentric, Open Label, Non-randomized, Interventional Study of Pembrolizumab in Combination With Electrochemotherapy in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma

Status: Completed, Estimated PCD: 2021-01-06

Clinical trial

Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Status: Terminated, Estimated PCD: 2020-01-30

Clinical trial

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-16

Clinical trial

Phase III Study of Neoadjuvant Chemotherapy With Capecitabine and Oxaliplatin Versus Chemoradiation for Locally Advanced Rectal Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2021-03-17

Clinical trial

Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Status: Recruiting, Estimated PCD: 2025-08-31

Clinical trial

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Status: Recruiting, Estimated PCD: 2025-03-31

Clinical trial

Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Status: Completed, Estimated PCD: 2023-09-28

Clinical trial

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Status: Recruiting, Estimated PCD: 2027-09-01

Clinical trial

Phase II Trial of Pulsed Dose Chemotherapy Plus Pembrolizumab in the First Line Treatment of Recurrent/Metastatic HNSCC

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

A Prospective Study of Hyperthermia Combined With Autologous Adoptive Cellular Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Status: Completed, Estimated PCD: 2022-12-31

Clinical trial

Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2020-12-30

Clinical trial

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy for Stage III Colon Cancer Patients Treated in Adjuvant Setting: Impact on Oxaliplatin-induced Sensitive Neurotoxicity. A Multicenter Phase II Randomized Trial (LEANOX)

Status: Active (not recruiting), Estimated PCD: 2022-07-28

Clinical trial

Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2026-07-28

Clinical trial

Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas

Status: Terminated, Estimated PCD: 2021-10-06

Clinical trial

A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy With Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Patients With Operable Adenocarcinoma of the Esophagus

Status: Terminated, Estimated PCD: 2011-10-01

Clinical trial

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Status: Withdrawn, Estimated PCD: 2022-12-14

Clinical trial

A Phase II Study of PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Status: Withdrawn, Estimated PCD: 2023-05-12

Clinical trial

ABLE: Phase II, Single Arm, Two-stage Study of Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

Status: Completed, Estimated PCD: 2023-06-23

Clinical trial

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors：NEO-ERA-01 Study

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies

Status: Completed, Estimated PCD: 2017-12-01

Clinical trial

A Phase II Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Status: Recruiting, Estimated PCD: 2026-07-30

Clinical trial

A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Risk Soft Tissue Sarcomas

Status: Completed, Estimated PCD: 2023-06-08

Clinical trial

A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)

Status: Terminated, Estimated PCD: 2021-01-20

Clinical trial

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma

Status: Terminated, Estimated PCD: 2022-05-01

Clinical trial

A Randomized, Open-label Phase II/III Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction and High Immune Responsiveness (MO30039/MO43340) - The DANTE Trial

Status: Recruiting, Estimated PCD: 2027-05-31

Clinical trial

A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

Phase II Study of Pembrolizumab as Salvage Therapy Among Multiple Myeloma Patients Progressing on CAR-T Cell Therapy

Status: Recruiting, Estimated PCD: 2024-10-21

Clinical trial

Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study

Status: Active (not recruiting), Estimated PCD: 2019-03-19

Clinical trial

A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-02-27

Clinical trial

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288

Status: Active (not recruiting), Estimated PCD: 2024-03-13

Clinical trial

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Status: Terminated, Estimated PCD: 2022-12-30

Clinical trial

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)

Status: Recruiting, Estimated PCD: 2026-08-29

Clinical trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2025-11-30

Clinical trial

A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Pilot Study of Immunotherapy Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

Perioperative Chemotherapy Plus PD-1 Antibody Compared With Perioperative Chemotherapy in the Locally Advanced Gastric Cancer: a Open-label, Phase 2 Randomised Controlled Trial

Status: Active (not recruiting), Estimated PCD: 2022-06-27

Clinical trial

A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Status: Recruiting, Estimated PCD: 2025-12-20

Clinical trial

A Window of Opportunity Study of Pembrolizumab in Colon Cancer

Status: Recruiting, Estimated PCD: 2025-03-19

Clinical trial

ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Status: Completed, Estimated PCD: 2020-01-01

Clinical trial

A Phase 2 Trial of Cabozantinib and Pembrolizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma

Status: Terminated, Estimated PCD: 2021-12-13

Clinical trial

A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer

Status: Completed, Estimated PCD: 2015-12-01

Clinical trial

Pilot Trial of Fecal Microbiota Transplantation and Re-Introduction of Anti-PD-1 Therapy in dMMR Colorectal Adenocarcinoma Anti-PD-1 Non-Responders

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-06-08

Clinical trial

A Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Pembrolizumab and Gemcitabine in Patients With HER2-negative Advanced Breast Cancer (ABC) "PANGEA-Breast"

Status: Completed, Estimated PCD: 2019-06-03

Clinical trial

Pembrolizumab and Radiotherapy for Previously Untreated Patients With Limited Stage NK/T Cell Lymphoma Who Are Not Eligible to Chemotherapy

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy (Stupp Protocol) in Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Phase IB Clinical Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab With or Without Chemotherapy in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma

Status: Completed, Estimated PCD: 2021-02-27

Clinical trial

Safety and Tolerability of Bexmarilimab Plus Pembrolizumab for Patients With Advanced (Inoperable or Metastatic) Non-small Cell Lung Cancer (NSCLC)

Status: Withdrawn, Estimated PCD: 2025-12-01

Clinical trial

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Status: Not yet recruiting, Estimated PCD: 2023-12-31

Clinical trial

Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer

Status: Active (not recruiting), Estimated PCD: 2023-12-31

Clinical trial

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase II Clinical Trial of Pembrolizumab in Combination With Carboplatin-paclitaxel in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer: MITO28/MANGO OV4 Study

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Photodynamic Priming to Facilitate Immunologic Activity of Anti-PD1 in Patients With Pancreatic Cancer

Status: Not yet recruiting, Estimated PCD: 2029-07-04

Clinical trial

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Status: Active (not recruiting), Estimated PCD: 2027-02-01

Clinical trial

Phase II Study of Irinotecan Liposomes Combined With 5-FU/LV+ Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

Neoadjuvant Immunotherapy in Rectal Cancer: A Pilot Study Examining the Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer

Status: Completed, Estimated PCD: 2023-09-25

Clinical trial

A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2027-02-24

Clinical trial

A Phase II Trial of Umbralisib and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Status: Terminated, Estimated PCD: 2021-09-14

Clinical trial

Enfortumab Vedotin in Combination With Pembrolizumab for Locally Advanced and/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE)

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Pembrolizumab in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

Status: Completed, Estimated PCD: 2021-11-02

Clinical trial

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

Status: Recruiting, Estimated PCD: 2026-06-01

Clinical trial

Combination of Pembrolizumab With Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer (PERICLES): A Phase II Study

Status: Not yet recruiting, Estimated PCD: 2023-07-01

Clinical trial

Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer

Status: Completed, Estimated PCD: 2024-01-30

Clinical trial

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

Status: Terminated, Estimated PCD: 2021-12-31

Clinical trial

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)

Status: Active (not recruiting), Estimated PCD: 2023-10-31

Clinical trial

Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy

Status: Terminated, Estimated PCD: 2022-09-01

Clinical trial

Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2025-09-01

Clinical trial

Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab or Pembrolizumab With Histology-Specific Chemotherapy for Operable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2025-08-27

Clinical trial

Pilot Feasibility Study of Intratumoral BO-112 in Combination With Pembrolizumab for Advanced Hepatocellular Carcinoma

Status: Terminated, Estimated PCD: 2023-03-13

Clinical trial

Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose IL-2 in Patients With Metastatic Melanoma

Status: Completed, Estimated PCD: 2022-10-12

Clinical trial

A Phase II, Single-arm Study of Combination Pembrolizumab and Olaparib in the Treatment of Patients With Advanced Cholangiocarcinoma

Status: Active (not recruiting), Estimated PCD: 2022-12-01

Clinical trial

The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Status: Terminated, Estimated PCD: 2022-07-31

Clinical trial

A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy. (SWIPE)

Status: Active (not recruiting), Estimated PCD: 2023-10-31

Clinical trial

Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Status: Completed, Estimated PCD: 2021-08-09

Clinical trial

NEO-SPACE Trial: Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin Followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

Status: Active (not recruiting), Estimated PCD: 2023-06-26

Clinical trial

A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG

Status: Completed, Estimated PCD: 2017-11-14

Clinical trial

A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases

Status: Active (not recruiting), Estimated PCD: 2024-05-31

Clinical trial

Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer

Status: Recruiting, Estimated PCD: 2023-11-01

Clinical trial

A Single-arm, Open-label, Multicenter Phase 2 Study to Evaluate XELOX + Tislelizumab in Combination With Doxorubicin Hydrochloride Liposome Injection （XELOX+PD-1+PLD）as Neoadjuvant Therapy for Resectable Gastric Cancer

Status: Recruiting, Estimated PCD: 2023-09-30

Clinical trial

Phase IIA Trial of Short-term Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/Gastroesophageal-junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2026-09-01

Clinical trial

A Phase 2a, Single-arm, Multi-center, Open-label Study of Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC Patients

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2024-11-30

Clinical trial

ASTEROID:A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours: Utilizing Triple IAP Blockade as a Strategy to Maximize Immunogenic Cell Death and the Generation of an Efficient Adaptive Immune Response

Status: Recruiting, Estimated PCD: 2026-03-16

Clinical trial

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2026-05-31

Clinical trial

Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma

Status: Active (not recruiting), Estimated PCD: 2025-03-31

Clinical trial

Phase II Multi-center Study of Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in NSCLC (Non-small Cell Lung Cancer) Patients With Targetable Genetic Alterations in Their Tumor Previously Treated With Appropriate Targeted Agents With Progressive Disease

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy

Status: Recruiting, Estimated PCD: 2024-07-08

Clinical trial

A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas

Status: Completed, Estimated PCD: 2022-06-01

Clinical trial

A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)

Status: Completed, Estimated PCD: 2018-05-08

Clinical trial

Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Completed, Estimated PCD: 2020-09-02

Clinical trial

Epigenetic Priming for Immune Therapy in ER-Positive Breast Cancer in Biomarker Select Population

Status: Terminated, Estimated PCD: 2023-06-15

Clinical trial

A Phase II Study to Explore the Neoadjuvant Treatment of Serplulimab Combined With CAPEOX + Celecoxib in the Treatment of Locally Advanced Rectal Cancer

Status: Recruiting, Estimated PCD: 2024-02-20

Clinical trial

A Multi-center, Phase II Study to Evaluate Safety and Efficacy of Adjuvant Chemotherapy With Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin and Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

Status: Active (not recruiting), Estimated PCD: 2023-09-09

Clinical trial

Calcium Electroporation in Combination With Irreversible Electroporation and Immunotherapy in Patients With Proficient Mismatch Repair System (pMMR) Metastatic Colorectal Cancer - A Prospective, Phase 2 Study

Status: Terminated, Estimated PCD: 2024-04-08

Clinical trial

Phase II Trial of Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

The Effect of Prebiotic Inulin on Patients Affected by Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Treated With Immune Checkpoint Inhibitors (ICIs): Princess Study

Status: Recruiting, Estimated PCD: 2024-12-02

Clinical trial

Phase Ib Trial Of Pembrolizumab And Nintedanib

Status: Recruiting, Estimated PCD: 2025-11-01

Clinical trial

BRE-03: Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Status: Recruiting, Estimated PCD: 2026-07-01

Clinical trial

A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Status: Active (not recruiting), Estimated PCD: 2025-03-01

Clinical trial

Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal Carcinoma

Status: Recruiting, Estimated PCD: 2026-01-09

Clinical trial

Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer

Status: Completed, Estimated PCD: 2022-06-01

Clinical trial

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Inoperable Patients

Status: , Estimated PCD: 2020-06-01

Clinical trial

Phenotyping of Blood Samples to Detect Autoimmune Signature Following Immunotherapy With Pembrolizumab

Status: Completed, Estimated PCD: 2019-10-01

Clinical trial

Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition

Status: Completed, Estimated PCD: 2021-02-28

Clinical trial

mFOLFOX6 Combined With Dalpiciclib(SHR6390) in Patients With Metastatic Colorectal Cancer (FIND): A Single-arm, Phase IIa Study.

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

A Prospective，Single Center, Randomized Control，Phase III Clinical Study for Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Patients With Stage ⅢB-Ⅳ NSCLC Who Failed With First-line Therapy

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

Fruquintinib Plus Arterial Infusion Therapy With Hepatic FOLFOX for Refractory Colorectal Cancer: The FAITH Randomized Clinical Trial

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2021-03-11

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)

Status: Completed, Estimated PCD: 2020-07-02

Clinical trial

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2027-04-27

Clinical trial

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Surgery, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Operable Patients

Status: , Estimated PCD: 2020-01-01

Clinical trial

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225

Status: Active (not recruiting), Estimated PCD: 2021-05-19

Clinical trial

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

Status: Recruiting, Estimated PCD: 2033-05-31

Clinical trial

Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2028-02-01

Clinical trial

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for MRF-negative Locally Advanced, pMMR Rectal Cancer: a Randomised, Phase 2 Trial

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

Neoadjuvant Pembrolizumab Plus Chemotherapy in Locally Advanced Sinonasal Carcinoma

Status: Not yet recruiting, Estimated PCD: 2026-11-01

Clinical trial

A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer

Status: Terminated, Estimated PCD: 2019-06-20

Clinical trial

mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: a Randomized Phase-II-trial

Status: Completed, Estimated PCD: 2021-01-11

Clinical trial

Phase 2, Randomized, Trial of Maintenance Letrozole/Abemaciclib vs Pembrolizumab After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wild-type Endometrial Cancer

Status: Not yet recruiting, Estimated PCD: 2027-09-01

Clinical trial

Pembrolizumab in Marginalzone Lymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Status: Recruiting, Estimated PCD: 2029-04-01

Clinical trial

Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Status: Completed, Estimated PCD: 2022-12-22

Clinical trial

UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

A Phase II Randomized Study to Determine the Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status: Completed, Estimated PCD: 2022-10-01

Clinical trial

Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2025-03-17

Clinical trial

A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma

Status: Completed, Estimated PCD: 2021-10-26

Clinical trial

Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2025-04-01

Clinical trial

A Phase Ib Study of Pembrolizumab Following Trans-Arterial Chemoembolization in Primary Liver Carcinoma

Status: Active (not recruiting), Estimated PCD: 2023-09-01

Clinical trial

A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Paclitaxel Weekly in ER-positive, Luminal B Metastatic Breast Cancer

Status: Withdrawn, Estimated PCD: 2023-06-01

Clinical trial

Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Status: Recruiting, Estimated PCD: 2024-09-30

Clinical trial

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Status: Recruiting, Estimated PCD: 2027-09-30

Clinical trial

Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

PD-1 Inhibitor Plus Chemotherapy as Conversion Therapy in Unresectable Gastric Cancer (STARS-GC01): A Single-arm, Single-center, Prospective Clinical Study.

Status: Completed, Estimated PCD: 2023-05-06

Clinical trial

An Interventional Phase II Study to Analyze the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Status: Active (not recruiting), Estimated PCD: 2026-06-01

Clinical trial

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

PD-1 Antibody Combined With Chemotherapy in High-risk Recurrent Nasopharyngeal Carcinoma: a Prospective, Open, Single-arm Phase II Clinical Trial

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy

Status: Completed, Estimated PCD: 2022-08-17

Clinical trial

A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC

Status: Completed, Estimated PCD: 2022-02-26

Clinical trial

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Status: Recruiting, Estimated PCD: 2028-04-01

Clinical trial

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Status: Active (not recruiting), Estimated PCD: 2024-08-30

Clinical trial

A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-03-01

Clinical trial

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Status: Active (not recruiting), Estimated PCD: 2025-04-02

Clinical trial

Induction, Concurrent and Adjuvant Nivolumab Combined With Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 2, Multi-center, Single-arm Clinical Trial

Status: Active (not recruiting), Estimated PCD: 2024-04-30

Clinical trial

A Pilot Study of Lenvatinib Plus Pembrolizumab in Patients With Advanced Sarcoma

Status: Active (not recruiting), Estimated PCD: 2025-03-01

Clinical trial

A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer

Status: Completed, Estimated PCD: 2023-01-03

Clinical trial

Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-05-31

Clinical trial

Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study

Status: Not yet recruiting, Estimated PCD: 2025-02-01

Clinical trial

A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors

Status: Terminated, Estimated PCD: 2012-01-01

Clinical trial

A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

Status: Recruiting, Estimated PCD: 2028-03-31

Clinical trial

A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)

Status: Completed, Estimated PCD: 2020-10-28

Clinical trial

Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma

Status: Active (not recruiting), Estimated PCD: 2017-09-30

Clinical trial

A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)

Status: Recruiting, Estimated PCD: 2025-07-18

Clinical trial

Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin. Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin and in Combination With Nivolumab in Patients With Peritoneal Carcinomatosis (PIANO)

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)

Status: Active (not recruiting), Estimated PCD: 2023-03-07

Clinical trial

A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Status: Recruiting, Estimated PCD: 2024-10-30

Clinical trial

A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma

Status: Recruiting, Estimated PCD: 2025-04-30

Clinical trial

A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With Melanoma

Status: Recruiting, Estimated PCD: 2025-01-31

Clinical trial

Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-lymphocyte (PD1-T) Combined With XELOX and Bevacizumab in the First-line Treatment of Recurrent and Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2023-08-01

Clinical trial

A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Status: Completed, Estimated PCD: 2024-04-11

Clinical trial

A Randomized, Multicenter, Open-label, Phase III Study to Compare the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab, Fluoropyrimidine-based and Platinum-based Chemotherapy (Hereinafter Referred to as "Chemotherapy") Versus Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Status: Active (not recruiting), Estimated PCD: 2027-02-01

Clinical trial

Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%: CJLSG1901

Status: Active (not recruiting), Estimated PCD: 2023-05-01

Clinical trial

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2038-12-31

Clinical trial

Short-course Radiotherapy Combined With CAPOX and Pd-1 Inhibitor for Locally Advanced Colon Cancer: a Randomized, Prospective, Multicentre, Phase II Trial (TORCH-C)

Status: Not yet recruiting, Estimated PCD: 2023-12-31

Clinical trial

A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-07-31

Clinical trial

CATRIPCA - A Phase I Study of PD1 Monoclonal Antibody (Pembrolizumab) In Combination With a IAP Antagonist (Debio 1143) In (Exocrine) Pancreatic And Colorectal Non MSI-high Advanced/Metastatic Adenocarcinoma.

Status: Completed, Estimated PCD: 2022-05-30

Clinical trial

Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSF

Status: Completed, Estimated PCD: 2021-06-21

Clinical trial

Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer

Status: Completed, Estimated PCD: 2021-01-20

Clinical trial

A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Status: Active (not recruiting), Estimated PCD: 2023-04-21

Clinical trial

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer: a Prospective, Multicenter, Single-arm Study

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

A Prospective, Open-Label, Single-Arm and Multicentre Phase II Study to Explore the Efficacy and Safety of Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Middle and Lower Locally Advanced Rectal Cancer

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Randomized Phase II Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Status: Not yet recruiting, Estimated PCD: 2026-06-30

Clinical trial

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With MDS

Status: Active (not recruiting), Estimated PCD: 2021-11-06

Clinical trial

A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum

Status: Terminated, Estimated PCD: 2022-03-22

Clinical trial

Combined Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC in PD-L1 Positive Patients (CPS≥1)

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer

Status: Completed, Estimated PCD: 2022-12-30

Clinical trial

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer

Status: Completed, Estimated PCD: 2015-11-01

Clinical trial

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

Status: Completed, Estimated PCD: 2022-02-22

Clinical trial

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)

Status: Active (not recruiting), Estimated PCD: 2024-03-06

Clinical trial

An Open Label Phase 2 Study on Propranolol and Pembrolizumab in Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma - a Scandinavian Sarcoma Group Collaboration

Status: Recruiting, Estimated PCD: 2028-01-01

Clinical trial

Toripalimab Combined With Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multi-center, Randomized Controlled Trial

Status: Active (not recruiting), Estimated PCD: 2025-05-01

Clinical trial

A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Status: Completed, Estimated PCD: 2022-05-31

Clinical trial

An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

Status: Completed, Estimated PCD: 2020-04-01

Clinical trial

Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH)

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

A Randomized Trial of Consolidative Immunotherapy With vs Without Thoracic Radiotherapy and / or Stereotactic Body Radiation Therapy (SBRT) After First-Line Systemic Therapy for Metastatic NSCLC

Status: Active (not recruiting), Estimated PCD: 2027-07-31

Clinical trial

A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

Status: Active (not recruiting), Estimated PCD: 2019-01-11

Clinical trial

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Status: Active (not recruiting), Estimated PCD: 2026-10-18

Clinical trial

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation

Status: Terminated, Estimated PCD: 2015-04-01

Clinical trial

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Tumor-Specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers (2020000584)

Status: Active (not recruiting), Estimated PCD: 2025-02-28

Clinical trial

A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Status: Active (not recruiting), Estimated PCD: 2022-07-18

Clinical trial

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

Status: Recruiting, Estimated PCD: 2028-05-30

Clinical trial

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T Cell (gdT) Therapy in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Status: Not yet recruiting, Estimated PCD: 2026-12-18

Clinical trial

Phase Ib/II Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

Status: Recruiting, Estimated PCD: 2026-12-30

Clinical trial

A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)

Status: Active (not recruiting), Estimated PCD: 2023-04-14

Clinical trial

iMmunoscore Associated Decision GuIdance for adjuvaNt Chemotherapy and Physical Exercise in Stage III Colon Cancer (iMAGINE): a Prospective, Randomized, Open-label, Multicenter, Phase III Clinical Trial

Status: Not yet recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Status: Terminated, Estimated PCD: 2022-12-30

Clinical trial

A Phase IB Study to Assess the Safety and Efficacy of Neoadjuvant Administration of Autologous Tumor Infiltrating Lymphocytes (LN144/Lifileucel) and Pembrolizumab for Treatment of Patients With Locally Advanced (Stage IIIB-D)/Metastatic (Stage IV) Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

A Phase I Trial of Intratumoral Administration of CCL21-Gene Modified Dendritic Cell (Ad-CCL21-DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC

Status: Active (not recruiting), Estimated PCD: 2024-01-11

Clinical trial

Pembrolizumab in Combination With Gemcitabine for Previously Treated Mycosis Fungoides and Sézary Syndrome: Efficacy and Characterization of Immune Response

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse Events

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients With Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2021-10-31

Clinical trial

A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer

Status: Completed, Estimated PCD: 2010-02-01

Clinical trial

A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination With Pembrolizumab in Subjects With Labyrinthin-Positive Adenocarcinomas

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma: A Prospective, Single-arm Study

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus

Status: Recruiting, Estimated PCD: 2025-10-31

Clinical trial

Single-Arm, Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)

Status: Recruiting, Estimated PCD: 2025-07-31

Clinical trial

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Status: Completed, Estimated PCD: 2022-12-20

Clinical trial

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Status: Recruiting, Estimated PCD: 2025-04-30

Clinical trial

A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

A Phase II Study of the Effects of Pembrolizumab on Quality of Life for Patients With Treatment-Naïve, Advanced or Metastatic NSCLC and Poor Performance Status

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Window of Opportunity Study With Neoadjuvant Pembrolizumab in Colorectal Cancer

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Neoadjuvant Checkpoint-based Immunotherapy Following Chemotherapy in Pancreatic Adenocarcinoma

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN

Status: Active (not recruiting), Estimated PCD: 2024-01-05

Clinical trial

Response Assessment to Pembrolizumab With Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging- A Pilot Study

Status: Active (not recruiting), Estimated PCD: 2023-12-31

Clinical trial

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Status: Recruiting, Estimated PCD: 2028-10-31

Clinical trial

A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies

Status: Active (not recruiting), Estimated PCD: 2020-07-14

Clinical trial

NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma: Investigating Induced Immune Context Changes

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma

Status: Completed, Estimated PCD: 2015-11-01

Clinical trial

Lung Cancer Cryo-Activation as a Novel Approach to Improve Cancer Immunogenicity and Augment Immunotherapy Efficacy

Status: Completed, Estimated PCD: 2023-06-27

Clinical trial

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Status: Recruiting, Estimated PCD: 2034-02-21

Clinical trial

A Randomized Phase II Study of CONsolidation PEmbrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol

Status: Active (not recruiting), Estimated PCD: 2024-01-01

Clinical trial

Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2021-04-16

Clinical trial

Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)

Status: Active (not recruiting), Estimated PCD: 2021-03-31

Clinical trial

First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid Tumors

Status: Recruiting, Estimated PCD: 2028-05-01

Clinical trial

A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2028-02-01

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of a Single Dose of Pembrolizumab in HIV-Infected Patients

Status: Recruiting, Estimated PCD: 2025-05-30

Clinical trial

Pilot Study of Serial Plasma Genotyping to Guide the Adaptive Treatment of Advanced NSCLC Receiving First-line Pembrolizumab

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

Status: Recruiting, Estimated PCD: 2026-03-30

Clinical trial

A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Status: Active (not recruiting), Estimated PCD: 2024-11-01

Clinical trial

A Phase I Study of Intraperitoneal 5FU+Oxaliplatin in Patients With Colorectal Cancer With Isolated Peritoneal Metastasis

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Status: Active (not recruiting), Estimated PCD: 2024-09-11

Clinical trial

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-09-01

Clinical trial

BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

Status: , Estimated PCD: 2027-02-23

Clinical trial

A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia

Status: Not yet recruiting, Estimated PCD: 2030-12-01

Clinical trial

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Status: Active (not recruiting), Estimated PCD: 2023-09-15

Clinical trial

A Single Arm Trial of Adjuvant Pembrolizumab in Patients With Limited Stage Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2028-05-31

Abstract

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Org: Medical Oncology Department, Rene Gauducheau Cancer Center, Institut De Cancerologie D'Ouest Centre Paul Papin, Hôpital Saint Grégoire, Faculté de Médecine Paris-Sud,

Abstract

Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.

Org: Fujian Medical University Union Hospital, Fuzhou, China, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Ruijin Hospital North, Shanghai Jiao Tong University School of Medcine, Shanghai, China, Dongguan Kang Hua Hospitcal, Dongguan, China, The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China,

Abstract

Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.

Org: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Division of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan, Research and Development Center for Medical Education, Department of Clinical Skills Education, Kitasato University School of Medicine, Sagamihara, Japan, Division of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan,

Abstract

Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).

Org: Institute of Clinical Medicine, University of Oslo, Institute of Clinical Sciences, Department of Surgery, The Sahlgrenska Academy, University of Gothenburg, Department of Biomedical and Clinical Sciences, Linköping University, Clatterbridge Cancer Centre NHS FT, School of Health Sciences, University of Skövde,

Abstract

ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.

Org: Shizuoka Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Beijing Cancer Hospital, Department of Oncology, National Taiwan University Hospital,

Abstract

Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.

Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,

Abstract

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.

Org: Sun Yat-sen University Cancer Centre, Collaborative Innovation Centre for Cancer Medicine, Hunan Cancer Hospital, Department of Radiation Oncology, Affiliated Hospital of Guizhou Medical University,

Abstract

PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer.

Org: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China, Biotherapy Center,

Abstract

Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW).

Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China, Astellas Pharma Global Development, Inc., Northbrook, IL, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Weill Cornell Medical College, New York, NY,

Abstract

Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).

Org: Servier Deutschland GmbH, Clinasses Inc, Clinassess Inc., Klinik und Poliklinik für Chirurgie, General and Visceral Surgery,

Abstract

Artificial intelligence (AI) analysis of tumor-infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) slides to explore immune phenotypes in papillary thyroid cancer.

Org: Lincoln Medical and Mental Health Center, Northwestern University Feinberg School of Medicine, Ascension Saint Francis Hospital, Lunit Inc., Oncology Therapeutic Development,

Abstract

A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.

Org: Stanford Cancer Center, Portuguese Oncology Institute of Porto, Porto, Portugal, The Kinghorn Cancer Centre, CUF Instituto de Oncologia, Macquarie University,

Abstract

The Quarterback trials: A phase 2 series of sequential studies of induction chemotherapy followed by reduced dose chemoradiation for human papillomavirus positive oropharynx cancer.

Org: Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, NYU Grossman School of Medicine, New York, NY, Rockefeller University, New York, NY, Icahn School of Medicine at Mount Sinai, New York, NY, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Summit Health, Clifton, NJ,

Abstract

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

Org: Memorial Sloan Kettering Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, Department of Radiology, Department of Colorectal Oncology,

Abstract

Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.

Org: Baylor College of Medicine, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, MD Anderson Cancer Center Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.

Org: Levine Cancer Institute, Atrium Health Carolinas Medical Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,

Abstract

Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer.

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.

Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,

Abstract

Landmark analysis of OS by response status in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the KEYNOTE-394 study.

Org: MSD China, Merck & Co., Inc.,

Abstract

Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.

Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, University of Chinese Academy of Sciences Cancer Hospital, Hepato-Pancreato-Biliary & Gastric Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences,

Abstract

Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).

Org: Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,

Abstract

Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Society for Immunotherapy of Cancer, The Cancer Institute Hospital of JFCR, Tokyo, Japan, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Astellas Pharma Global Development,

Abstract

Org: Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Berlin, Germany, Charité– Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet Zu Berlin, Berlin, Germany, Klinikum Neuperlach/ Klinikum Harlaching, Department of Hematology, Oncology, and Palliative Care, Munich, Germany, Klinik Dr. Hancken GmbH, Department of Hematology, Oncology, and Palliative Care, Stade, Germany, Kliniken Maria Hilf GmbH, Moenchen-Gladbach, Germany, Oncological Practice UnterEms, Leer, Germany, University Medical Center Goettingen, Department of Gastroenterology, Gastrointestinal Oncology, and Endocrinology, Goettingen, Ge...,

Abstract

Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance.

Org: Roswell Park Comprehensive Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,

Abstract

Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.

Org: Akershus University Hospital (Ahus), Lorenskog, Sørlandet Hospital, Kristiansand, St.Olav's University Hospital,

Abstract

Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Org: Abramson Cancer Center at the University of Pennsylvania, University of Pennsylvania, Department of Biostatistics, Epidemiology, and Informatics,

Abstract

NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven.

Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute,

Abstract

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.

Org: Innovent Biologics, Inc.,

Abstract

Olaparib (O) + ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial.

Org: AstraZeneca, University Hospitals Leuven, Leuven, Belgium, The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Seoul National University College of Medicine, Christie Hospital NHS Foundation Trust and the University of Manchester,

Abstract

A phase 2 trial of chemotherapy, pembrolizumab, and propranolol in patients with advanced esophageal/gastroesophageal junction adenocarcinoma (EGAC).

Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY, Division of GI Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, Roswell Park Cancer Institute,

Abstract

Capped F10, a novel DNA directed fluoropyrimidine, in TP53 mutated acute myeloid leukemia (AML).

Org: Comprehensive Cancer Center of Atrium Health Wake Forest Baptist,

Abstract

Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR): A multicenter, randomized, open-label, phase 2/3 trial.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Division of Gastroenterological Surgery, Saitama Cancer Center, Kurume University School of Medicine, Teikyo University Chiba Medical Center,

Abstract

Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes.

Org: Mayo Clinic Arizona, Phoenix, AZ, Caris Life Sciences, Irving, TX, Mayo Clinic, Department of Medicine, Duke University Medical Center, Caris MPI,

Abstract

Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).

Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,

Abstract

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.

Org: Yonsei Cancer Center, Yonsei University Health System, Maria Sklodowska-Curie National Research Institute of Oncology, James Lind Cancer Research Center, Temuco, Chile, Harbin Medical University Cancer Hospital, Asan Medical Center,

Abstract

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

Org: Washington University School of Medicine in St Louis, Natco Pharma, NATCO Pharma Limited,

Abstract

MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.

Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center,

Abstract

A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.

Org: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, Cardiff University, School of Medicine, Cardiff, United Kingdom, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, United Kingdom,

Abstract

Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and personalized chemotherapy in PDAC.

Org: Cancer Research Center of Marseille (CRCM), Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, CNRS UMR 5309-INSERM U1209, Institut Paoli-Calmettes, Marseille, France, Aix-Marseille University CHU Timone,

Abstract

Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.

Org: Duke University Medical Center, Personalis, Inc., University of North Carolina at Chapel Hill, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,

Abstract

Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.

Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, University of Michigan Health System Comprehensive Cancer Center, Hospital Universitari Vall d'Hebron Research Institute, Roswell Park Cancer Institute,

Abstract

Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.

Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Medical Oncology 1, Department of Oncology, Veneto Institute of Oncology IOV–IRCCS, Padova, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy,

Abstract

Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,

Abstract

Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategies.

Org: Mount Sinai Beth Israel, Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai,

Abstract

Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial.

Org: Asan Medical Center, Chonnam National University Hwasun Hospital, National Cancer Center Hospital East, Kashiwa, Japan, Keimyung University Dongsan Hospital, Yonsei Cancer Center, Yonsei University Health System,

Abstract

A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.

Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan, National Cancer Center Hospital East, Japan, Kashiwa-Shi, Japan, Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan,

Abstract

Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial.

Org: Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China, Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China, Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China,

Abstract

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.

Org: University of Florida/UF Health Cancer Center, University of Florida Health Cancer Center, Orlando Health Cancer Institute, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,

Abstract

Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.

Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,

Abstract

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

Org: Renmin Hospital of Wuhan University, Xiantao First People’s Hospital, Jianghan Oilfield General Hospital, The Central Hospital of Xiao Gan, Xiang Yang Central Hospital,

Abstract

Pre-treatment plasma-informed circulating tumor DNA detection as an early identification of therapeutic benefit for patients with untreated advanced lung squamous cell carcinoma.

Org: Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China, Genecast Biotechnology Co., Ltd., Wuxi, China, Beijing, China, Genecast Biotechnology Co., Ltd., Beijing, China,

Abstract

Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).

Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, Hubei, China,

Abstract

AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).

Org: BeiGene (USA) Co., Ltd., BeiGene (Shanghai) Co., Ltd., Sarah Cannon Research Institute/Tennessee Oncology, Monash Heath and Faculty of Medicine, Nursing and Health Sciences, Mayo Clinic,

Abstract

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Org: University of Texas MD Anderson Cancer Center, The University of Pittsburgh, NRG Oncology SDMC, NSABP Foundation, Inc., UMPC Hillman Cancer Center,

Abstract

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.

Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,

Abstract

SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Org: MD Anderson Cancer Center, Brown University - Lifespan Cancer Institute, Hospital de Clinicas de Porto Alegre, Samsung Medical Center, Pusan National University Hospital,

Abstract

BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Org: MD Anderson Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Asan Medical Center, Hammersmith Hospital, Imperial College, London, United Kingdom, Department of Gastroenterology/Digestive Oncology,

Abstract

A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.

Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,

Abstract

Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.

Org: University Hospital 12 de Octubre, Perth Oncology, Western Health,

Abstract

Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.

Org: NHMRC Clinical Trials Centre, The University of Sydney, Northern Beaches Hospital, University of Adelaide, Campbelltown Hospital,

Abstract

Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis.

Org: The First Hospital of China Medical University, Shenyang, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of China Medical University,

Abstract

Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).

Org: Gustave Roussy Département d'Organisation du Parcours Patient, Institut Paoli Calmettes, Centre Hospitalier Lyon Sud, ICM Val d'Aurelle, CHU Nantes-Department of Hepato-Gastroenterology,

Abstract

Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.

Org: Jina Pharmaceuticals, Intas Pharmaceuticals Ltd.,

Abstract

Real-world outcomes by race in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the informCLL registry.

Org: Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, Lymphoma Research Foundation, New York, NY, Janssen, Horsham, PA, Janssen Scientific Affairs, LLC, Horsham, PA,

Abstract

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.

Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), NRG Oncology SDMC, The University of Pittsburgh, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute,

Abstract

The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)—ISRCTN83842641.

Org: University of Leeds, University of Glasgow, University of Birmingham, Patient representative, Christie NHS Foundation Trust, Manchester, United Kingdom,

Abstract

Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).

Org: Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, H. Universitario Reina Sofía, Universidad de Córdoba, Hospital Universitario Miguel Servet, CIBERONC-ISCIII,

Abstract

Assessment of sociodemographic disparities in outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE.

Org: Georgetown University Medical School, AstraZeneca, Centre Hospitalier Universitaire Vaudois (CHUV),

Abstract

STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Org: Mass General Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Arcus Biosciences, Gilead Sciences, Inc., Memorial Sloan Kettering Cancer Center,

Abstract

FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).

Org: Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany, Bruederkrankenhaus St. Josef Paderborn, Technical University Munich, Universitätsklinikum Freiburg Klinik Für Innere Medizin II Gastrointestinale Onkologie, Onkologische und Hamatologische Schwerpunktpraxis,

Abstract

10-year outcomes of technically unresectable oral cancers with neoadjuvant chemotherapy: Real-world data and implications for clinical practice.

Org: Tata Memorial Centre, Mumbai, India,

Abstract

Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study.

Org: Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Cliniques Universitaires Saint-Luc, Department of Gastroenterology, Division of Digestive Oncology, Centre Léon Bérard,

Abstract

TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

Org: Institute of Cancer, Xinqiao Hospital, Chongqing, China, Guangdong TCRCure Biopharma Technology Co., Ltd, Guangzhou, China, Biomedical Analysis Center, Chongqing, China, TCRCure Biopharma Corp., Los Angeles, CA, Institute of Molecular and Cell biology & Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore,

Abstract

A phase II clinical trial of prior regimen rechallenge in third- or later-line treatment for patients with metastatic colorectal cancer.

Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shangai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,

Abstract

The impact of cancer prehabilitation on psychological outcomes and quality of life in patients with gastro-oesophageal cancer.

Org: Imperial College, London Regional Cancer Center, Imperial College Healthcare NHS Trust,

Abstract

Description of technique for endoscopic ultrasound-guided tissue acquisition in pancreatic cancer for comprehensive molecular profiling: Results of a randomized trial.

Org: Orlando Health Cancer Institute, Digestive Health Institute, Temple University Hospital, Philadelphia, PA,

Abstract

Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Center GF Leclerc, Georges-François Leclerc Cancer Center, Georges François Leclerc Cancer Center – UNICANCER, Dijon, France, William Morey Hospital,

Abstract

Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses.

Org: Beijing Tongren Hospital, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,

Abstract

Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy in combination with lenvatinib and PD-1 inhibitors.

Org: The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Sun Yat-sen University State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Genecast Biotechnology Co., Ltd, Beijing, China,

Abstract

A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.

Org: Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Klinikum rechts der Isar, Technische Universität München, Charité–Universitätsmedizin Berlin,

Abstract

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric adenocarcinoma (FRUTINEOGA): A multicenter, phase II study.

Org: Guangxi Medical University Cancer Hospital, Guangxi Medical University Affiliated Tumor Hospital, Wuming Hospital of Guangxi Medical University,

Abstract

Anal carcinoma: A retrospective analysis in a Mexican cohort.

Org: Centro Universitario contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”,

Abstract

Adjuvant chemotherapy in ypStage III locally advanced rectal cancer after neoadjuvant treatment with an oxaliplatin-based regimen.

Org: The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, SYSU, Guangzhou JOYO Pharma, Guangdong Ruishun Biotech,

Abstract

Proteomic profiling of FOLFOX-resistant colorectal cancer cells.

Org: Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University,

Abstract

Adverse events in real-world patients covered by Medicare with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX.

Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,

Abstract

Prognostic impact of primary tumor sidedness in stage III colorectal cancer.

Org: PPG Oncologia, Faculdade de medicina UFC, Universidade de São Paulo (FMUSP), Núcleo de Oncologia da Bahia (NOB)- Grupo Oncoclínicas, Moffitt Cancer Center,

Abstract

Exploring the clinical significance of specific immune-related adverse events (irAE) in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy.

Org: Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, Or-Yeuda, The Ella Lemelbaum Institute for Immuno-Oncology and Melanoma at Sheba Medical Center, Ella Lemelbaum Institute for Immuno Oncology , Sheba Medical Center,

Abstract

The adjuvant oxaliplatin-irinotecan paradox.

Org: Alara Medical Group, University of Texas Medical Branch at Galveston, UTMB Health,

Abstract

A pragmatic, single-arm clinical trial of a dose-adjustment algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy.

Org: Dartmouth Cancer Center, Lebanon, NH, Dartmouth Cancer Center, Nashua, NH, Dartmouth Cancer Center, St. Johnsbury, VT,

Abstract

First clinical study reporting safety and outcomes of high dose oxaliplatin use in PIPAC for colorectal peritoneal carcinomatosis.

Org: Aster International Institute of Oncology, Bangalore, India,

Abstract

The prognostic impact of NKA dynamics in first-line treatment of metastatic colorectal cancer.

Org: Department of Biochemistry & Immunology, Danish Colorectal Cancer Center South, Institute of Regional Health Research, University Hospital of Southern Denmark, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Real-world treatment patterns and total cost of care in Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX.

Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,

Abstract

A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib and tislelizumab in unresectable hepatocellular carcinoma.

Org: Guangxi Medical University Cancer Hospital, Nanning, China,

Abstract

First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial.

Org: Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Yoko Biomedical,

Abstract

Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers.

Org: University of Chicago Medical Center, Chicago, IL, University of Chicago, Department of Medicine, Icahn School of Medicine at Mount Sinai, Section of Hematology & Oncology, University of Illinois Chicago,

Abstract

Therapeutic potential of dual CDK12 and 13 inhibition in colorectal cancer.

Org: UMass Chan Medical School, Duke University Medical Center,

Abstract

Hypertriglyceridemia associated with the use of capecitabine in a Mexican cohort.

Org: Hospital Ángeles Lindavista, Arké SMO,

Abstract

Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).

Org: Ruijin Hospital, Shanghai Jiaotong University School, Shanghai, China, Shanghai Jiao Tong University School of Medicine, Jiading Central Hospital, Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi Branch of Ruijin Hospital,

Abstract

Safety and tolerability of HLX07 combined with chemotherapy in patients with advanced solid tumors.

Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, Inc.,

Abstract

A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.

Org: Virginia Cancer Specialists, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,

Abstract

The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer.

Org: Amplia Therapeutics, Melbourne, Australia, Australian Catholic University, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia,

Abstract

Association of treatment regimens with quality of life and overall survival in patients with metastatic colorectal cancer in Peru.

Org: Oncosalud-AUNA, San Borja, Peru,

Abstract

Long-term survivors (LTSs) population of metastatic colorectal cancer (mCRC): A Northern Italian comprehensive cancer center experience.

Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, AUSL-IRCCS Reggio Emilia,

Abstract

Effect of overexpression of ERK1/2 and MDR1 on chemoresistance in advanced gastric cancer patients.

Org: Chittaranjan National Cancer Institute, Chiittaranjan National Cancer Institute,

Abstract

Patterns of treatment switching and healthcare resource utilization differences among real-world Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX.

Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,

Abstract

Establishing functional models of peritoneal carcinomatosis using MicroOrganoSphere (MOS) technology.

Org: University of Texas MD Anderson Cancer Center, Xilis Inc, Xilis Inc., University of Texas at MD Anderson Cancer Center, Xilis, Inc.,

Abstract

Atezolizumab plus bevacizumab combined with transarterial embolization plus hepatic arterial infusion-chemotherapy for unresectable hepatocellular carcinoma with a diameter larger than 8 cm: A retrospective study.

Org: Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center Gansu Hospital, Sun Yat-sen University State Key Laboratory of Oncology in South China,

Abstract

Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.

Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Radiology, Sun Yat-sen Memorial hospital of Sun Yat-sen university, Guangzhou, China,

Abstract

Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice.

Org: Medical Day Hospital Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Day Hospital Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pharmacy Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori-University of Milan,

Abstract

Chemoembolization plus hepatic arterial infusion chemotherapy combined with donafenib, anti-PD-1 antibody for unresectable hepatocellular carcinoma (uHCC): A retrospective analysis.

Org: haerbin medical university cancer hospital,

Abstract

In vivo anti-tumor effects of XON7 in association with ICIs.

Org: Xenothera, Nantes, France,

Abstract

The safety and efficacy of cadonilimab in combination with AK117 (anti-CD47 antibody) plus chemotherapy as first-line treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.

Org: Akeso Biopharma, Inc., Zhongshan, China,

Abstract

Translational analysis of combination of 5-fluorouracil (FU), interferon (IFN)-alpha2, and nivolumab in unresectable fibrolamellar liver cancer.

Org: Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center,

Abstract

Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models.

Org: Brenus Pharma, Clermont-Ferrand, France, Inovotion, Explicyte Immuno-Oncology, Institut de Recherche en Cancérologie de Montpellier, Center Georges François Leclerc,

Abstract

Obesity and toxic habits as avoidable determinants of chronic peripheral neuropathy induced by chemotherapy (NPCIQ): NeuroPredict project.

Org: Reina Sofía University Hospital, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, CIBERONC,

Abstract

Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer?

Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA, PainReform,

Abstract

Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial.

Org: Qilu Hospital of Shandong University, Jinan, China National Biotec Group, Linyi Cancer Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China,

Abstract

Effect of MDSC-targeted TFF2-MSA with PD-1 blockade therapy in advanced gastric cancer models.

Org: Columbia University Medical Center, Tonix Pharmaceuticals, Columbia University - Mailman School of Public Health,

Abstract

Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC).

Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, The Ohio State University James Cancer Center, The James Cancer Hospital and Solove Research Institute,

Abstract

Carboplatin and paclitaxel chemoradiation for localized anal cancer in patients not eligible for mitomycin and 5-fluorouracil.

Org: University of Wisconsin Carbone Cancer Center,

Abstract

Key factors associated with response in the treatment of liver metastatic melanoma by cryoablation combined with PD-1 blockade therapy: The Cryo-Fire-001 study.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Biotherapy Center,

Abstract

The antinociceptive effects of selective TRPV1 antagonist RCI002 against chemotherapy-induced peripheral neuropathy.

Org: Rudacure, Hallym University Medical Center, Gachon University Gil Medical Center,

Abstract

Efficacy and safety of nab-paclitaxel+cisplatin/nedaplatin + S-1 as an induction chemotherapy regimen for locally advanced hypopharyngeal cancer.

Org: Affiliated Hospital of Guilin Medical University, Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University,

Abstract

Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase 2, single-arm trial.

Org: First Affiliated Hospital of Zhengzhou University, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Anyang Tumor Hospital,

Abstract

A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab.

Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Arthur G. James Cancer Hospital, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, College of Public Health at Temple University, Ohio State University Comprehensive Canvcer Hospital,

Abstract

Donafenib, anti-PD-1 antibodies, plus hepatic arterial infusion chemotherapy (HAIC) as conversion therapy in patients with initially unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, phase 2 study.

Org: The Fifth Medical Center of the PLA General Hospital, The Fifth Medical Center of Chinese PLA General Hospital,

Abstract

Oxaliplatin based chemotherapy for advanced well-differentiated neuroendocrine tumors: A systematic review and meta-analysis.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan, China National Biotec Group,

Abstract

Arterial chemotherapy in advanced hepatocellular carcinoma: An evolutionary trajectory exploration and pooled outcome analysis.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma,

Abstract

High dose methotrexate (MTX) treatment: Value of post treatment MTX level monitoring and risk factors for acute kidney injury.

Org: Maimonides Medical Center, Brooklyn, NY, Maimonides Cancer Center,

Abstract

Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience.

Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Baltimore, MD,

Abstract

Efficacy of vemurafenib based regimens in colorectal cancer: A systematic review of clinical trials.

Org: New York Medical College - Saint Michael's Medical Center, Saint Michael's Medical Center, St. Michael's Medical Ctr, Reg Cancer Ctr At St Michael's Medical Ctr,

Abstract

Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study.

Org: The Second Affiliated Hospital Of Nanchang University, Nanchang, China National Biotec Group,

Abstract

Clinical outcomes of extramammary Paget’s disease in Korea: A multicenter, retrospective study.

Org: Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea, Asan Medical Center, Seoul National University Hospital, Samsung Medical Center, Seoul St. Mary's Hospital,

Abstract

Sex difference in tolerability of adjuvant oxaliplatin-based chemotherapy for colorectal cancer and changes in diagnostic components of sarcopenia: A prospective study.

Org: Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan, Department of Surgical Oncology, The Univeristy of Tokyo, Tokyo, Japan, Department of Geriatric Medicine, The University of Tokyo, Tokyo, Japan,

Abstract

Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA.

Org: Onkologie Ravensburg, University Women’s Hospital, Paracelsus Medical University, Winicker Norimed GmbH, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,

Abstract

A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML).

Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, University of Texas at MD Anderson Cancer Center,

Abstract

Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.

Org: Genesis Research, Ipsen Biopharmaceuticals, Inc., Dan Duncan Comprehensive Cancer Center, Baylor College of Medicine,

Abstract

Total neoadjuvant therapy for locally advanced rectal cancer: A western Australian experience.

Org: UWA Medical School, University of Western Australia & Linear Clinical Research, Department of Medical Oncology, Fiona Stanley Hospital, Colorectal Unit, Department of General Surgery, St. John of God Midland Hospital, Icon Cancer Centre, Midland,

Abstract

Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study).

Org: Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital Southern Medical University, Guangzhou, China, Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China,

Abstract

Adverse events in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.

Org: Dan Duncan Comprehensive Cancer Center, Baylor College of Medicine, Genesis Research, Ipsen Biopharmaceuticals, Inc.,

Product

mFOLFOX6 + bevacizumab + atezolizumab

Abstract

Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.

Org: FibroFighters Foundation, Rush University Medical Center, University of Zürich, Columbia University - Mailman School of Public Health, UPMC Health Plan,

Product

5-Fluorouracil/Oxaliplatin + nivolumab + ipilimumab + chemoradiation + surgery

Product

NALIRIFOX

Product

FLOT with empegfilgrastim

Product

Gemcitabine, nab-paclitaxel, Oxaliplatin

Product

FG-M108 plus CAPOX

Product

XELOX plus menadione